

case study

Enrolling 20% of All U.S. Patients for a Phase III Hypertension Trial with Narrow Inclusion Criteria

Context

In a Phase III trial targeting patients with CKD and hypertension, Panoramic Health is exceeding enrollment expectations despite representing only ~5% of participating sites. Narrow, complex eligibility criteria made recruitment challenging, yet the network significantly outperformed its target.

Objectives

Panoramic Health was selected to enroll patients for this study, which aims to assess the effectiveness of drug therapy in participants with CKD and high blood pressure.

- **National enrollment goal:** 440 patients
- **Panoramic enrollment goal:** 70 patients across 18 network sites
- **Target population:** Adults age >18 with CKD and hypertension

Process

Panoramic Science streamlines enrollment through a data-driven funnel. EMR queries and chart reviews flag eligible patients, who are then referred by their treating nephrologist through a defined intake process. Central teams coordinate pre-screens, while rapid scheduling ensures patients move quickly from consent to enrollment.

Because research occurs in the patient's own nephrology clinic with their trusted physician, participation does not cause undue burden on patients.

Impact

By enrolling 20% of all U.S. patients in the trial while representing just ~5% of sites, Panoramic Health demonstrates its ability to deliver outsized value and accelerate trial success.

- **91 patients enrolled** across 18 Panoramic Health sites
- **Exceeded enrollment target by 30%**
- Contributed **20% of total U.S. enrollment** for the entire trial, while only representing just **~5% of enrolling sites**